Observational Axillary Lymph Node Dissection Study TNBC HER2+ Basel Switzerland
ClinicalTrials.gov Studies
Summary
The OPBC-11/MACRONAC Study (NCT07546695) has been registered on ClinicalTrials.gov as an observational multicenter retrospective cohort study. The study aims to determine the safety of omitting axillary lymph node dissection in patients with triple negative breast cancer and HER2+ tumors who have residual macrometastases after neoadjuvant chemotherapy. Data will be collected from medical records at the University Hospital of Basel, Switzerland, using an existing oncological breast surgery database initiated in 2016.
“In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN/TAD/TAS or MARI node) after NAC.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new observational clinical study has been registered on ClinicalTrials.gov under identifier NCT07546695. The OPBC-11/MACRONAC study is a multicenter retrospective cohort study being conducted at the University Hospital of Basel, Switzerland, examining whether axillary lymph node dissection can be safely omitted in patients with triple negative breast cancer and HER2+ tumors who have residual macrometastases following neoadjuvant chemotherapy. The study will use existing data from the Oncological Breast Surgery Database established in 2016. For healthcare providers and clinical investigators, this registry entry represents informational content about an ongoing research program in breast cancer surgical oncology. The study's findings, once published, may inform clinical practice regarding axillary management strategies in neoadjuvant treatment responders.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study
Observational NCT07546695 Kind: OBSERVATIONAL Apr 23, 2026
Abstract
In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN/TAD/TAS or MARI node) after NAC.
Conditions: Breast Cancer
Interventions: Data Collection from medical records of from an already existing database "ONCOLOGICAL BREAST SURGERY DATABASE OF THE UNIVERSITY HOSPITAL OF BASEL" which was initiated in 2016.
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.